Cytokeratin profiles of male breast cancers

Ciocca, Vincenzo; Bombonati, Alessandro; Gatalica, Zoran; Pasquale, Marcello Di; Milos, Anthony; Ruiz-Orrico, Alejandra; Dreher, Donna; Folch, Nathalie; Monzon, Federico A.; Santeusanio, Giuseppe; Perou, Charles M.; Bernard, Philip S.; Palazzo, Juan

doi:10.1111/j.1365-2559.2006.02519.x

Cited by 32 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MBC is similar to female breast cancer (FBC) in many ways, but there are also distinct differences [4][5][6]. The diseases are histologically similar, invasive ductal carcinoma being the most frequent form in both MBC and FBC, while lobular cancer is less common in men [5,7]. Furthermore, MBC tumors express estrogen (ER) and progesterone (PR) receptors more frequently than do FBC tumors, while HER2 seems to be less frequently overexpressed/amplified [4,5,8].…”

Section: Introductionmentioning

confidence: 95%

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

Johansson

Nilsson

Berglund

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Male breast cancer (MBC) is extremely rare and poorly characterized on the molecular level. Using high-resolution genomic data, we aimed to characterize MBC by genomic imbalances and to compare it with female breast cancer (FBC), and further to investigate whether the genomic profiles hold any prognostic information. Fifty-six fresh frozen MBC tumors were analyzed using high-resolution tiling BAC arrays. Significant regions in common between cases were assessed using Genomic Identification of Significant Targets in Cancer (GISTIC) analysis. A publicly available genomic data set of 359 FBC tumors was used for reference purposes. The data revealed a broad pattern of aberrations, confirming that MBC is a heterogeneous tumor type. Genomic gains were more common in MBC than in FBC and often involved whole chromosome arms, while losses of genomic material were less frequent. The most common aberrations were similar between the genders, but high-level amplifications were more common in FBC. We identified two genomic subgroups among MBCs; male-complex and male-simple. The male-complex subgroup displayed striking similarities with the previously reported luminal-complex FBC subgroup, while the male-simple subgroup seems to represent a new subgroup of breast cancer occurring only in men. There are many similarities between FBC and MBC with respect to genomic imbalances, but there are also distinct differences as revealed by high-resolution genomic profiling. MBC can be divided into two comprehensive genomic subgroups, which may be of prognostic value. The male-simple subgroup appears notably different from any genomic subgroup so far defined in FBC.

show abstract

Section: Introductionmentioning

confidence: 95%

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

Johansson

Nilsson

Berglund

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Os dados a respeito dos perfis de expressão gênica são limitados. Recentemente, Ciocca et al 23 publicaram estudo descrevendo os perfis de citoqueratinas expressos no câncer de mama masculino em casos da América do Norte e da Europa. O painel de anticorpos utilizados foi CK 5/6, 14, 17, 18 e 19 associado ao receptor de estrogênio.…”

Section: Histopatologiaunclassified

Câncer de mama em homens

Nogueira¹,

Mendonça²,

Pasqualette³

2014

Rev. Bras. Mastol.

View full text Add to dashboard Cite

Keywords RESUMOO câncer de mama em homens é uma doença pouco conhecida. Sua abordagem em ensaios clínicos e publicações é pouco frequente. Foi realizada uma revisão da literatura, priorizando a epidemiologia, os fatores de risco, a patologia e os marcadores tumorais da doença. Corresponde a 1% de todas as neoplasias da mama. Os fatores de risco incluem hiperestrogenismo, idade, ascendência judaica, história familiar e síndrome de Klinefelter. Cerca de 90% dos tumores são ductais invasivos. De 80 a 90% dos casos apresentam receptores de estrógeno e progesterona positivos. O tratamento é semelhante ao do câncer de mama na mulher: cirurgia, hormonioterapia, quimioterapia e radioterapia são usadas, seguindo os guidelines femininos. Os fatores prognós-ticos incluem tamanho tumoral, grau histológico e comprometimento linfonodal. O câncer de mama é similar em homens e mulheres; todavia, os casos masculinos apresentam particularidades imuno-histoquímicas, mas não existem estudos suficientes para avaliar o impacto dessa característica no prognóstico e tratamento dessa neoplasia. ABSTRACT Breast cancer in men is a little known disease. His approach in clinical trials

show abstract

“…They had a higher histological grade and a larger size than tumors that were not of the basal subtype. The basal subtype should identify a subset of pathologically aggressive MBC, as in FBC [25]. …”

Section: Discussionmentioning

confidence: 99%

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

Sánchez-Muñoz¹,

Román-Jobacho

Pérez-Villa

et al. 2012

Oncology

View full text Add to dashboard Cite

Aim: The aim of this study was to assess the molecular subtype profiles of male breast cancer (MBC) and subsequent clinical outcome using a validated 6-marker immunohistochemical panel. Methods: A total of 43 cases of MBC were examined retrospectively using a semiquantitative immunohistochemical analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (Her2), epidermal growth factor receptor and cytokeratin 5/6. Patients were classified into the following categories: luminal A, luminal B, Her2-positive or basal-like subtypes. Results: The median age of patients was 63 years (r: 32–89). The predominant histology was invasive ductal carcinoma (91%). Only 1 patient had advanced breast cancer at diagnosis. Ninety-three percent were ER-positive and 84% were PR-positive. Two patients had tumors that were ER- and PR-negative. The distribution of tumor molecular subtypes was 19 (44%) luminal A, 22 (51%) luminal B and 2 (5%) basal-like. The Her2-positive tumor subtype was not identified. The clinicopathological characteristics did not differ significantly between tumor subtypes A and B. There were no significant differences in 6-year disease-free survival (74 vs. 82%, p = 0.77) or overall survival (74 vs. 82%, p = 0.69) between luminal A and luminal B subtypes, respectively. Conclusion: The most common subtypes in our cohort of MBC were luminal B followed by luminal A, and no differences were found between both tumor subtypes in terms of clinicopathologic characteristics and patient outcome.

show abstract

Cytokeratin profiles of male breast cancers

Abstract: Male breast carcinomas have a basal-like phenotype that is similar in frequency to that of female breast carcinomas. The expression of CK5/6 and CK14 identifies a subset of pathologically aggressive male breast cancers.

Cited by 32 publications

References 20 publications

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer

Câncer de mama em homens

Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization

Contact Info

Product

Resources

About